Business Context and Reporting Period
The filing is Landec Corporation’s Form 10-K for the fiscal year ended May 25, 2014, not a Lifecore Biomedical standalone filing or a calendar-quarter filing. Lifecore Biomedical is Landec’s HA-based Biomaterials subsidiary. Landec operates through Food Products Technology, Food Export, and HA-based Biomaterials segments, serving food, packaging, medical, pharmaceutical, and veterinary markets.
Apio’s Food Products Technology business sells branded and private-label fresh produce using BreatheWay packaging. Its Food Export business buys and sells produce, primarily to Asia. Lifecore manufactures pharmaceutical-grade sodium hyaluronate and provides aseptic filling and contract development services.
Key Financial Metrics
| Metric | FY2014 | FY2013 |
|---|---|---|
| Revenue | $476.8 million | $441.7 million |
| Gross profit | $62.6 million | $62.8 million |
| Gross margin | 13.1% | 14.2% |
| Operating income | $20.2 million | $24.9 million |
| Operating margin | 4.2% | 5.6% |
| Net income attributable to common stockholders | $19.1 million | $22.6 million |
| Diluted EPS | $0.71 | $0.85 |
| Cash flow from operations | $21.0 million | $21.2 million |
| Capital expenditures | $14.9 million | $8.9 million |
| Cash and cash equivalents | $14.2 million | $13.7 million |
| Total debt | $34.4 million | $40.3 million |
FY2014 revenue increased 8%. Food Products Technology revenue rose 13% to $360.7 million, Food Export revenue declined 11% to $69.8 million, and HA-based Biomaterials revenue increased 11% to $45.7 million. Lifecore revenue growth reflected a 32% increase in aseptic filling revenue, partly offset by a 13% decline in fermentation sales.
Landec generated $21.0 million of operating cash flow, used $13.3 million in investing activities and used $7.2 million in financing activities. Debt declined by approximately $5.9 million during the year, including $9.9 million of net payments on lines of credit and long-term debt, partly offset by $2.3 million of common-stock proceeds.
Material Changes Versus the Prior Comparable Period
- Revenue increased by $35.1 million, but gross profit was essentially flat because of adverse produce quality and yield conditions, higher labor costs, and lower processing yields.
- Management estimated that operational variances reduced Food Products Technology operating income by approximately $9.3 million, primarily because of heavy Midwest and East Coast rains and temperature swings in California.
- Operating income decreased 19% and diluted EPS decreased from $0.85 to $0.71. FY2013 benefited from a $3.9 million reversal of the GreenLine acquisition earn-out liability; no comparable benefit occurred in FY2014.
- SG&A increased 8% to $35.2 million, while research and development expense decreased 22% to $7.2 million as the company reduced corporate R&D and licensing collaborations.
- Cash flow from operations was stable despite higher receivables and a $10.0 million non-cash increase in the fair value of the Windset investment.
- Capital expenditures increased substantially to $14.9 million to expand Apio processing capacity and upgrade Lifecore facilities and equipment.
- The company changed the annual testing date for goodwill and other indefinite-lived intangible assets to the first day of the fourth fiscal quarter. No impairment was recorded; estimated fair value was 136% of book value for Food Products Technology and 176% for HA-based Biomaterials.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management stated that existing cash, cash equivalents, marketable securities, and internally generated operating cash flow were expected to fund operational and capital requirements for at least the next twelve months. The filing does not provide specific revenue, earnings, or margin guidance.
- Apio’s results are exposed to weather, crop quality and yields, produce prices, seasonality, perishability, and fixed processing costs.
- Customer concentration is significant: the top five customers represented approximately 42% of FY2014 revenue; Costco represented approximately 21% and Walmart approximately 11%.
- International sales represented approximately 29% of FY2014 revenue, exposing the company to import restrictions, political and regulatory risks, tariffs, and currency-related demand effects.
- Several raw materials and services are sourced from single suppliers or providers, creating disruption and pricing risks.
- Lifecore and other operations are subject to FDA, foreign regulatory, quality-system, environmental, and product-liability requirements.
- Windset was carried at Level 3 fair value of $39.6 million. FY2014 included $10.0 million of unrealized fair-value income and $1.1 million of dividend income from the investment, making reported earnings sensitive to valuation assumptions.
- At May 25, 2014, contractual obligations totaled approximately $55.7 million, including $34.4 million of debt principal, $5.2 million of estimated interest, $11.0 million of operating leases, and $5.0 million of produce purchase commitments.
- Apio and Lifecore were in compliance with their financial covenants at year-end. The company reported no legal proceedings.
- Subsequent to year-end, Apio paid $11.0 million for additional Windset securities, increasing common-stock ownership from 20.1% to 26.9%. Apio also amended its revolving credit facility, increasing capacity from $25 million to $40 million, reducing the spread to LIBOR plus 1.75%, and extending the maturity to July 2019.
- Management reported effective disclosure controls and internal control over financial reporting as of May 25, 2014. The filing notes a prior material weakness and restatement involving the quarter ended August 26, 2012.
Most Important Facts to Verify
- Confirm that the intended issuer is Landec Corporation and that the relevant period is the fiscal year ended May 25, 2014; the supplied metadata identifies Lifecore Biomedical and “2013 Q4.”
- Reconcile earnings quality by separating operating profit from the $10.0 million unrealized Windset fair-value gain and $1.1 million dividend income.
- Assess whether Apio’s $9.3 million weather- and yield-related operating impact was temporary or reflects structural processing and sourcing issues.
- Review customer concentration, especially Costco and Walmart, and the effect of international demand and Indonesian import quotas on Food Export revenue.
- Evaluate liquidity after the $14.9 million capital-spending program, scheduled debt principal payments, purchase commitments, and the post-year-end $11.0 million Windset investment.
- Examine the assumptions supporting the $39.6 million Level 3 Windset valuation and the company’s goodwill and intangible-asset impairment sensitivity.